Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6578845 | 0.95 | DUT (0.38) | CA2CA1DUT | |
| SCHEMBL6655379 | 0.89 | DUT (0.35) | CA2CA1DUT | |
| SCHEMBL6577285 | 0.88 | DUT (0.35) | CA2CA1DUTCA12CA9 | |
| SCHEMBL11903406 | 0.83 | CA1 (0.32) | CA2CA1 | |
| SCHEMBL11903403 | 0.82 | CA1 (0.31) | CA2CA1 | |
| SCHEMBL3522762 | 0.79 | — | — | |
| SCHEMBL4188554 | 0.79 | USP2 (0.44) | CA2CA1DUTCA12CA9 | |
| SCHEMBL1032931 | 0.77 | CA2 (0.47) | CA2CA1CA9 | |
| SCHEMBL2354578 | 0.76 | — | — | |
| SCHEMBL12012236 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113735880-B | Preparation method of everolimus and intermediate thereof | 鲁南制药集团股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-113929703-B | Synthesis method of everolimus related substance D | 鲁南制药集团股份有限公司 | 2023-12-01 | — | — | CN | claimed |
| CN-113929703-A | Synthesis method of everolimus related substance D | 鲁南制药集团股份有限公司 | 2022-01-14 | — | — | CN | claimed |
| US-9079921-B2 | Processes for preparation of Everolimus and intermediates thereof | BIOCON LIMITED (IN) | 2015-07-14 | — | — | US | claimed |
| EP-2640730-A1 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF | Biocon Limited (IN) | 2013-09-25 | — | — | EP | claimed |
| US-20130225823-A1 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF | BIOCON LIMITED (IN) | 2013-08-29 | — | — | US | claimed |
| WO-2012066502-A1 | PROCESSES FOR PREPARATION OF EVEROLIMUS AND INTERMEDIATES THEREOF | BIOCON LIMITED (IN) | 2012-05-24 | — | — | WO | claimed |
| US-20070166357-A1 | Bandage For Facilitating Transdermal Respiration And Healing | PEACH TECHNOLOGIES LLC | 2007-07-19 | — | — | US | claimed |
| EP-1216251-B1 | REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES | WYETH CORP (US) | 2003-02-26 | — | — | EP | claimed |
| EP-1216251-A2 | REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES | Wyeth (US) | 2002-06-26 | — | — | EP | claimed |
| US-20010039338-A1 | Regioselective synthesis of rapamycin derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-11-08 | — | — | US | claimed |
| US-6277983-B1 | Regioselective synthesis of rapamycin derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2001-08-21 | — | — | US | claimed |
| WO-2001023395-A2 | REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| US-20240173305-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-30 | — | — | US | disclosed |
| EP-3813946-B1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-22 | — | — | EP | disclosed |
| CN-116813642-B | Everolimus purification method | 浙江康润制药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-0867438-A1 | Rapamycin derivatives and their use, particularly as immunosuppressants | Novartis AG (CH) | 1998-09-30 | — | — | EP | disclosed |
| US-5665772-A | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants | SANDOZ LTD. (CH) | 1997-09-09 | — | — | US | disclosed |
| EP-0663916-A1 | O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS | SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H. (AT) | 1995-07-26 | — | — | EP | disclosed |
| WO-1994009010-A1 | O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039338-A1 | Regioselective synthesis of rapamycin derivatives | RICTOR, MTOR, RPTOR | CA2 3981/4885CA1 4378/4885DUT 2476/4885 |
| US-20240173305-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | CA2 4583/4885CA1 4755/4885DUT 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.